MET and gastric cancer: Diagnostic assays of MET overexpression/amplification are not as homogeneous in gastric cancer compared to non-small-cell lung cancer (NSCLC), where the MET exon-14-skipping mutation has been extensively investigated and a clear strategy has been set out.